156 related articles for article (PubMed ID: 15777203)
1. Signal transduction by IL-2 and its receptors as target in treatment of rheumatoid arthritis.
Kozanidou VI; Theocharis AD; Georgiadis A; Voulgari PV; Drosos AA; Karamanos NK
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):41-50. PubMed ID: 15777203
[TBL] [Abstract][Full Text] [Related]
2. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy.
Drosos AA
Drugs; 2002; 62(6):891-907. PubMed ID: 11929337
[TBL] [Abstract][Full Text] [Related]
3. [Rheumatoid arthritis and cytokines].
Kaneko S; Kondo Y; Yokosawa M; Sumida T
Nihon Rinsho; 2016 Jun; 74(6):913-8. PubMed ID: 27311178
[TBL] [Abstract][Full Text] [Related]
4. [Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts].
Seemayer CA; Distler O; Kuchen S; Müller-Ladner U; Michel BA; Neidhart M; Gay RE; Gay S
Z Rheumatol; 2001 Oct; 60(5):309-18. PubMed ID: 11759230
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in rheumatoid arthritis.
Köller MD
Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
[TBL] [Abstract][Full Text] [Related]
6. The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis.
Wu Y; Pan W; Hu X; Zhang A; Wei W
Biochem Pharmacol; 2021 Jan; 183():114360. PubMed ID: 33301760
[TBL] [Abstract][Full Text] [Related]
7. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis.
Azizi G; Jadidi-Niaragh F; Mirshafiey A
Int J Rheum Dis; 2013 Jun; 16(3):243-53. PubMed ID: 23981743
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy.
Alam J; Jantan I; Bukhari SNA
Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758
[TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes.
Hot A; Miossec P
Ann Rheum Dis; 2011 May; 70(5):727-32. PubMed ID: 21345813
[TBL] [Abstract][Full Text] [Related]
10. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy.
Xu WD; Zhang M; Zhang YJ; Ye DQ
Hum Immunol; 2013 Sep; 74(9):1057-60. PubMed ID: 23800433
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-2 as a treatment for psoriasis.
Salim A; Emerson R
Curr Opin Investig Drugs; 2001 Nov; 2(11):1546-8. PubMed ID: 11763155
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis.
Benedetti G; Miossec P
Eur J Immunol; 2014 Feb; 44(2):339-47. PubMed ID: 24310226
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators.
van de Loo FA; van den Berg WB
Rheum Dis Clin North Am; 2002 Feb; 28(1):127-49. PubMed ID: 11840694
[TBL] [Abstract][Full Text] [Related]
14. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
15. The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features.
Semenzato G; Pizzolo G; Zambello R
Int J Clin Lab Res; 1992; 22(3):133-42. PubMed ID: 1520910
[TBL] [Abstract][Full Text] [Related]
16. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-22 and rheumatoid arthritis: emerging role in pathogenesis and therapy.
Xie Q; Huang C; Li J
Autoimmunity; 2015 Mar; 48(2):69-72. PubMed ID: 25483133
[TBL] [Abstract][Full Text] [Related]
18. Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.
Lu Y; Xiao J; Wu ZW; Wang ZM; Hu J; Fu HZ; Chen YY; Qian RQ
Phytomedicine; 2012 Jul; 19(10):882-9. PubMed ID: 22673798
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
Franke S; Herrmann D; Hein G; Müller A; Stein G
Eur J Med Res; 1997 Sep; 2(9):401-6. PubMed ID: 9300938
[TBL] [Abstract][Full Text] [Related]
20. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
